Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Ixabepilone

Nature Reviews Drug Discovery volume 6, pages 953–954 (2007)Cite this article

Abstract

Ixabepilone (Ixempra; Bristol-Myers Squibb), a cytotoxic microtubule inhibitor, was approved by the US FDA for the treatment of metastatic breast cancer in October 2007. It is the first member of the epothilone family of anticancer agents to be approved.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Ixabepilone.

References

  1. Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nature Rev. Cancer 4, 253–265 (2004).

    Article  CAS  Google Scholar 

  2. Cortes, J. & Baselga, J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 12, 271–280 (2007).

    Article  CAS  PubMed  Google Scholar 

  3. Bollag, D. M. et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55, 2325–2333 (1995).

    CAS  PubMed  Google Scholar 

  4. Lee, F. Y. et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 7, 1429–1437 (2001).

    CAS  PubMed  Google Scholar 

  5. Food and Drug Administration. FDA labelling information [online], (2007).

  6. Vahdat, L. T. et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes. J. Clin. Oncol. 25, 18S (2007).

    Google Scholar 

  7. Perez, E. A. et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 25, 3407–3414 (2007).

    Article  CAS  PubMed  Google Scholar 

  8. Sledge, G. W. Jr et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J. Clin. Oncol. 21, 588–592 (2003).

    Article  PubMed  Google Scholar 

  9. Fumoleau, P. et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur. J. Cancer 40, 536–542 (2004).

    Article  CAS  PubMed  Google Scholar 

  10. Reichardt, P. et al. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann. Oncol. 14, 1227–1233 (2003).

    Article  CAS  PubMed  Google Scholar 

  11. Blum, J. L. et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 17, 485–493 (1999).

    Article  CAS  PubMed  Google Scholar 

  12. Wist, E. A. et al. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol. 43, 186–189 (2004).

    Article  PubMed  Google Scholar 

  13. Pivot, X. et al. Ixabepilone in patients (pts) with metastatic breast cancer (MBC) that is resistant to an anthracycline, a taxane and capecitabine. Ann. Oncol. 17, ix70 (2006).

    Google Scholar 

  14. Baselga, J. et al. Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). Breast Cancer Res. Treat 94, S31 (2005).

    Google Scholar 

  15. IMS MIDAS Quantum (2007).

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Alison Conlin, Monica Fornier and Clifford Hudis are at the Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY 1002, USA. conlina@mskcc.org fornierm@mskcc.org hudisc@mskcc.org,

    Alison Conlin, Monica Fornier & Clifford Hudis

  2. Santwana Kar is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. skar@uk.imshealth.com,

    Santwana Kar

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Alison Conlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica Fornier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clifford Hudis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Santwana Kar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Conlin, A., Fornier, M., Hudis, C. et al. Ixabepilone. Nat Rev Drug Discov 6, 953–954 (2007). https://doi.org/10.1038/nrd2469

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2469

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing